Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06449274
Other study ID # KY2023-156-1
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date June 2026

Study information

Verified date June 2024
Source Harbin Medical University
Contact Haibo Jia
Phone 15945685291
Email jhb101180@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this imaging substudy of RESTORE trial is to demonstrate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in improving plaque stabilization in patients with acute coronary syndrome.


Description:

The present study is an integrated imaging substudy of randomized, controlled and intervention trial of preventive drug-coated balloon angioplasty in vulnerable atherosclerotic plaque (RESTORE). The RESTORE Imaging trial will equally enroll from the DCB arm and GDMT arm to at least 180 consecutive individuals to validate the superiority of drug-coated balloon (DCB) treatment on non-flow limited vulnerable plaque as compared to guideline-directed medical therapy (GDMT) in enlarge luminal dimensions.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 180
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Subjects must be between 18 and 80 years of age 2. Subject must present with acute myocardial infarction or unstable angina planned for PCI 3. Successful stent implantation (i.e., residual stenosis less than 20%) must be done in culprit lesions and any lesions with ischemia evidence (e.g., QFR equal or less than 0.8) 4. Subject must have at least one native non-culprit lesion with visually estimated stenosis of 40-80% and QFR >0.8 5. Target lesion must have a visually estimated diameter of 2.0-4.0 mm and length of = 50 mm 6. Target lesion must have any two of the intravascular imaging criteria of PB >65%, MLA <3.5 mm^2 (OCT) or 4.0mm^2 (IVUS), FCT <75 µm, or maximal lipid arc >180° 7. Subject must provide written informed consent before any study-related procedure Exclusion Criteria: 1. Subject has known hypersensitivity or contraindication to any of the study drugs (including all asprin, P2Y12 inhibitors, one or more components of the study devices, including paclitaxel, etc) that cannot be adequately pre-medicated 2. Subject is receiving immunosuppressant therapy or has known immunosuppressive or severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., human immunodeficiency virus, systemic lupus erythematosus, etc.) 3. Hypotension, shock, or need for mechanical support or intravenous vasopressors; 4. Creatinine clearance =30 ml/min/1.73 m^2 (as calculated by MDRD formula for estimated GFR) 5. Left ventricular ejection fraction<30% by the most recent imaging test within 30 days before procedure (echo, MRI, contrast left ventriculography or others) 6. Life expectancy <2 years for any 7. Subject is currently participating in another investigational drug or device clinical study that has not yet completed its primary endpoint 8. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results. 9. The target lesion is located within 10 mm of the proximal or distal of stent 10. The target lesion cannot be in the left main coronary artery 11. The target lesion is located in a bifurcation lesion (i.e., the diameter of the branch vessels is >2 mm with >50% of stenosis) 12. The target lesion is located in severe calcification or tortuosity of vessels 13. The target lesion involved in the ostium of LAD, LCX or RCA (within 3 mm of the ostium) 14. The target lesion is located within the bypass graft artery

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Drug-coated balloon
Non-culprit lesion will be pretreated before DCB treatment. The bail-out stent treatment is permitted if pretreatment failed. Individual will receive guideline-directed medical treatment.
Drug:
Guideline-directed medical treatment
All individuals will receive guideline-directed medical treatment.

Locations

Country Name City State
China The Second Affiliated Hospital of Harbin Medical University Harbin Heilongjiang

Sponsors (2)

Lead Sponsor Collaborator
Harbin Medical University Shanghai Shenqi Medical Technology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Minimal lumen area (MLA) OCT-MLA At 12 months
Secondary Absolute change and percent change of MLA; Absolute change of MLA (mm2) is defined as the difference between baseline and follow-up MLA in OCT imaging. Percent change of MLA (%) is defined as absolute change of MLA divided by baseline MLA. At 12 months
Secondary Absolute change and percent change of maximum plaque burden (PB); Absolute change of maximum PB (%) is defined as the difference between baseline and follow-up PB in IVUS imaging. Percent change of plaque burden (%) is defined as absolute change of PB divided by baseline PB. At 12 months
Secondary Absolute change and percent change of fibrous cap thickness (FCT); Absolute change of FCT (µm) is defined as the difference between baseline and follow-up FCT in OCT imaging. Percent change of FCT (%) is defined as absolute change of FCT divided by baseline FCT. At 12 months
Secondary Absolute change and percent change of maximum lipid arc; Absolute change of maximum lipid arc (°) is defined as the difference between baseline and follow-up maximum lipid arc in OCT imaging. Percent change of maximum lipid arc (%) is defined as absolute change of maximum lipid arc divided by baseline maximum lipid arc. At 12 months
Secondary Percentage of participants with FCT <75 µm At 12 months
Secondary Percentage of participants with FCT <65 µm; At 12 months
Secondary Percentage of participants with PB >65%; At 12 months
Secondary Percentage of participants with PB >70%; At 12 months
Secondary Percentage of participants with MLA <3.5 mm2; At 12 months
Secondary Percentage of participants with maximal lipid arc >180°; At 12 months
Secondary Percentage of participants with positive remodeling; Positive remodeling is defined as Remodeling index (cross sectional area (CSA) of external elastic membrane (EEM) in lesion divided by CSA of EEM in reference vessel) >1.05. At 12 months
Secondary Percentage of participants with macrophages; Macrophage will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
Secondary Percentage of participants with lipid plaques; Lipid plaque will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
Secondary Percentage of participants with microchannels; Microchannels will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
Secondary Percentage of participants with cholesterol crystal; Cholesterol crystal will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
Secondary Percentage of participants with calcification; Calcification will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
Secondary Percentage of participants with healed plaque; Healed plaque will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
Secondary Percentage of participants with non-culprit plaque rupture. Non-culprit plaque rupture will be categorized into 0 representing its absence and 1 representing presence at 12 months imaging. At 12 months
See also
  Status Clinical Trial Phase
Terminated NCT00385138 - Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Phase 3
Completed NCT01944800 - Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Phase 4
Completed NCT02290080 - Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers Phase 3
Completed NCT02286544 - Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers Phase 1
Completed NCT01405287 - Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT Phase 2
Completed NCT00767507 - Maintenance of Platelet Inhibition With Cangrelor Phase 2
Completed NCT03672097 - Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT00399880 - Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes N/A
Completed NCT02430493 - Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients N/A
Completed NCT01994577 - Optimum Troponin Cutoffs for ACS in the ED
Completed NCT00313300 - Safety Study of Apixaban in Recent Acute Coronary Syndrome Phase 2
Completed NCT02244710 - EndoTic - Endothelium and Ticagrelor N/A
Active, not recruiting NCT04090281 - Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Phase 4
Active, not recruiting NCT03581578 - VITROS Immunodiagnostic Products hs Troponin I
Recruiting NCT04116931 - OPTImal Management of Antithrombotic Agents: OPTIMA-5 Phase 4
Completed NCT02171065 - PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. N/A
Completed NCT00855257 - Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome Phase 3
Completed NCT02733341 - The Effect of IV Cangrelor and Oral Ticagrelor Study Phase 4
Completed NCT02184884 - Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
Completed NCT00932100 - A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome Phase 2